Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Apremilast Oral Suspension vs Tablet and Food Effect
NCT02641353Phase 1Completed
- Sponsor
- Amgen
- Start
- Jan 2016
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apremilast in plaque psoriasis and psoriatic arthritis (PsA) (3 arms), sponsored by Amgen. Primary endpoints: Maximum Observed Plasma Concentration at 72 hours, Area Under the Concentration-time Curve From Time Zero to Last Measured Time Point at 72 hours and 7 more. Started Jan 2016; status: completed.
02
Drugs
apremilast
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02641353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02641353.